Literature DB >> 8251312

Prostacyclin in diarrhoea-associated haemolytic uraemic syndrome.

C M Taylor1, C J Lote.   

Abstract

The role of prostacyclin (PGI2) in the pathogenesis of haemolytic uraemic syndrome (HUS) is controversial. In part, confusion has been caused by failure to distinguish between two main sub-types of the syndrome: extrinsic, diarrhoea-associated HUS (D+ HUS), usually caused by infection with verocytotoxin-producing Escherichia coli or Shigella dysenteriae, and the heterogeneous group of non-prodromal forms where intrinsic factors predominate (D- HUS). This paper critically reviews data confined to D+ HUS. Two methods have been used to assess PGI2 synthesis; the generation of PGI2 from endothelium in the presence of HUS plasma in vitro and the measurement of stable metabolites in body fluids. No concensus could be reached with regard to the former. The reported increase of PGI2 stable metabolites in plasma may represent reduced clearance or increased carriage by plasma lipids. Apparent differences between studies of urinary excretion of PGI2 metabolites may reflect the way excretion was expressed. If the metabolite concentration is factored for urinary creatinine, it appears that renal excretion and thus renal synthesis of PGI2 is reduced. However, these are insufficient data on which to attribute the pathogenesis of D+ HUS to disordered PGI2 metabolism.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8251312     DOI: 10.1007/bf00852530

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  34 in total

Review 1.  Urinary bladder prostanoids--their synthesis, function and possible role in the pathogenesis and treatment of disease.

Authors:  D P Mikhailidis; J Y Jeremy; P Dandona
Journal:  J Urol       Date:  1987-03       Impact factor: 7.450

2.  Prostacyclin infusion in haemolytic-uraemic syndrome of children.

Authors:  T J Beattie; A V Murphy; M L Willoughby; J J Belch
Journal:  Br Med J (Clin Res Ed)       Date:  1981-08-15

3.  Reversible deficient prostacyclin release in childhood hemolytic uremic syndrome.

Authors:  D A Chamone; W C Proesmans; L A Monnens; P Binda ki Muaka; J G Vermylen
Journal:  Int J Pediatr Nephrol       Date:  1982-03

4.  Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation.

Authors:  G A FitzGerald; B Smith; A K Pedersen; A R Brash
Journal:  N Engl J Med       Date:  1984-04-26       Impact factor: 91.245

5.  Disturbances of prostacyclin metabolism in children with hemolytic-uremic syndrome and in first degree relatives.

Authors:  S Túri; T J Beattie; J J Belch; A V Murphy
Journal:  Clin Nephrol       Date:  1986-04       Impact factor: 0.975

6.  Vitamin E treatment of haemolytic uraemic syndrome.

Authors:  H R Powell; D A McCredie; C M Taylor; J R Burke; R G Walker
Journal:  Arch Dis Child       Date:  1984-05       Impact factor: 3.791

7.  Intravascular platelet activation in the hemolytic uremic syndrome.

Authors:  M D Walters; M Levin; C Smith; T J Nokes; R M Hardisty; M J Dillon; T M Barratt
Journal:  Kidney Int       Date:  1988-01       Impact factor: 10.612

8.  The rat urinary bladder produces prostacyclin as well as other prostaglandins.

Authors:  J Y Jeremy; D P Mikhailidis; P Dandona
Journal:  Prostaglandins Leukot Med       Date:  1984-11

9.  The influence of age on renal prostaglandin synthesis in man.

Authors:  A Hornych; F Forette; J Bariéty; C Krief; J Aumont; M Paris
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  1991-07       Impact factor: 4.006

10.  Absence of plasma prostacyclin stimulating activity deficiency in hemolytic uremic syndrome.

Authors:  N Schlegel; J Maclouf; C Loirat; L Drouet; R Marotte; P Y Scarabin; H Mathieu
Journal:  J Pediatr       Date:  1987-07       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.